文献速递药物不良反应与药物警戒

哌拉西林-他唑巴坦致骨髓抑制严重程度与影响因素的相关性:多因素有序logistic回归分析

Correlation between severity of myelosuppression caused by piperacillin-tazobactam and factors: Analysis through a multivariate ordered logistic regression mode.
PubMed 文献 · Br J Clin Pharmacol · 2026-08-07

本研究基于近10年电子数据库及某市药品不良反应监测系统数据,纳入115例哌拉西林-他唑巴坦致骨髓抑制患者,采用多因素有序logistic回归分析严重程度及症状出现时间的影响因素。结果显示合并用药显著增加骨髓抑制严重程度风险(OR=3.95,p<0.001),男性、既往病史和用药疗程延长加速症状出现。停药后80.0%患者症状改善,但24.3%患者因骨髓抑制延长原病程。

要点

  • 合并用药是哌拉西林-他唑巴坦致骨髓抑制严重程度的关键风险因素(OR=3.95,p<0.001)。
  • 男性、既往病史和长期用药者症状出现更快,需加强早期监测。
  • 停药后80.0%患者症状改善,但24.3%患者原病程延长。

核心结论

  • 合并用药尤其是多重用药是哌拉西林-他唑巴坦致骨髓抑制严重程度的关键风险因素。
  • 男性、有既往病史和长期用药患者需加强早期监测。

研究设计与样本

  • 基于电子数据库和某市药品不良反应监测系统近10年数据,纳入115例哌拉西林-他唑巴坦致骨髓抑制患者。
  • 采用多因素有序logistic回归模型分析影响严重程度和症状出现时间的因素。

主要发现

  • 合并用药显著增加骨髓抑制严重程度风险(OR=3.95,p<0.001)。
  • 男性(OR=4.03,p=0.02)、既往病史(OR=4.25,p<0.01)和用药疗程延长(OR=1.60,p<0.0001)加速症状出现。
  • 用药后白细胞显著下降(2.2×10^9/L vs. 9.1×10^9/L),血小板显著下降(25.5×10^9/L vs. 222.5×10^9/L),p<0.001。
  • 停药后80.0%患者症状改善,但24.3%患者因骨髓抑制延长原病程。

临床怎么用

  • 对合并用药尤其是多重用药患者,应警惕哌拉西林-他唑巴坦相关骨髓抑制的严重风险。
  • 对男性、有既往病史和长期用药患者,建议加强早期血液学监测。
  • 出现骨髓抑制时应及时评估停药,并关注原病程可能延长的风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To explore the factors influencing the severity of piperacillin-tazobactam-associated myelosuppression and the time of symptom onset and to provide a basis for clinical risk prevention and control. METHODS: Based on the electronic database and data from a city's adverse drug reaction monitoring system in the past 10 years, 115 patients with piperacillin-tazobactam-induced myelosuppression were included. Multivariate ordered logistic regression models were used to analyse the factors affecting severity and time to symptom onset. RESULTS: Concomitant medication significantly increased the risk of myelosuppression severity (OR = 3.95, p < 0.001). Male (OR = 4.03, p = 0.02), past medical history (OR = 4.25, p < 0.01) and prolonged duration of medication (OR = 1.60, p < 0.0001) accelerated symptom onset. Laboratory indices showed a significant decrease in leucocytes (2.2 × 109/L vs. 9.1 × 109/L) and platelets (25.5 × 109/L vs. 222.5 × 109/L) after medication (p < 0.001). Symptomatic improvement was observed after discontinuation of the medication in 80.0% of the patients, but prolongation of the original course of the disease due to myelosuppression was observed in 24.3% of the patients. CONCLUSION: Concomitant medication, especially multiple medication, is a key risk factor for the severity of myelosuppression, and early monitoring needs to be strengthened in males, those with past medical history and long-term medication users. This study provides data support for individualized medication regimens and risk warnings.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Li MT, Mo RX, Guan JK, et al. Correlation between severity of myelosuppression caused by piperacillin-tazobactam and factors: Analysis through a multivariate ordered logistic regression mode. Br J Clin Pharmacol. 2026. PMID: 42568272. doi:10.1002/bcp.70720

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。